These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 32680929)

  • 1. Automated Segmentation of Baseline Metabolic Total Tumor Burden in Diffuse Large B-Cell Lymphoma: Which Method Is Most Successful? A Study on Behalf of the PETRA Consortium.
    Barrington SF; Zwezerijnen BGJC; de Vet HCW; Heymans MW; Mikhaeel NG; Burggraaff CN; Eertink JJ; Pike LC; Hoekstra OS; Zijlstra JM; Boellaard R
    J Nucl Med; 2021 Mar; 62(3):332-337. PubMed ID: 32680929
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interobserver Agreement on Automated Metabolic Tumor Volume Measurements of Deauville Score 4 and 5 Lesions at Interim
    Zwezerijnen GJC; Eertink JJ; Burggraaff CN; Wiegers SE; Shaban EAIN; Pieplenbosch S; Oprea-Lager DE; Lugtenburg PJ; Hoekstra OS; de Vet HCW; Zijlstra JM; Boellaard R
    J Nucl Med; 2021 Nov; 62(11):1531-1536. PubMed ID: 33674403
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Impact of Semiautomatic Segmentation Methods on Metabolic Tumor Volume, Intensity, and Dissemination Radiomics in
    Driessen J; Zwezerijnen GJC; Schöder H; Drees EEE; Kersten MJ; Moskowitz AJ; Moskowitz CH; Eertink JJ; Vet HCW; Hoekstra OS; Zijlstra JM; Boellaard R
    J Nucl Med; 2022 Sep; 63(9):1424-1430. PubMed ID: 34992152
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quantitative Radiomics Features in Diffuse Large B-Cell Lymphoma: Does Segmentation Method Matter?
    Eertink JJ; Pfaehler EAG; Wiegers SE; van T; Brug D; Lugtenburg PJ; Hoekstra OS; Zijlstra JM; de Vet HCW; Boellaard R
    J Nucl Med; 2022 Mar; 63(3):389-395. PubMed ID: 34272315
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Optimizing Workflows for Fast and Reliable Metabolic Tumor Volume Measurements in Diffuse Large B Cell Lymphoma.
    Burggraaff CN; Rahman F; Kaßner I; Pieplenbosch S; Barrington SF; Jauw YWS; Zwezerijnen GJC; Müller S; Hoekstra OS; Zijlstra JM; De Vet HCW; Boellaard R;
    Mol Imaging Biol; 2020 Aug; 22(4):1102-1110. PubMed ID: 31993925
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combatting the effect of image reconstruction settings on lymphoma [
    Ferrández MC; Eertink JJ; Golla SSV; Wiegers SE; Zwezerijnen GJC; Pieplenbosch S; Zijlstra JM; Boellaard R
    EJNMMI Res; 2022 Jul; 12(1):44. PubMed ID: 35904645
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Prognostic value of pretreatment (18)F-FDG PET-CT for patients with advanced diffuse large B-cell lymphoma].
    Ding CY; Guo Z; Sun J; Yang WP; Li TR
    Zhonghua Zhong Liu Za Zhi; 2018 Jul; 40(7):528-533. PubMed ID: 30060362
    [No Abstract]   [Full Text] [Related]  

  • 8. Deep-Learning
    Capobianco N; Meignan M; Cottereau AS; Vercellino L; Sibille L; Spottiswoode B; Zuehlsdorff S; Casasnovas O; Thieblemont C; Buvat I
    J Nucl Med; 2021 Jan; 62(1):30-36. PubMed ID: 32532925
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combination of baseline metabolic tumour volume and early response on PET/CT improves progression-free survival prediction in DLBCL.
    Mikhaeel NG; Smith D; Dunn JT; Phillips M; Møller H; Fields PA; Wrench D; Barrington SF
    Eur J Nucl Med Mol Imaging; 2016 Jul; 43(7):1209-19. PubMed ID: 26902371
    [TBL] [Abstract][Full Text] [Related]  

  • 10. To evaluate prognostic significance of metabolic-derived tumour volume at staging 18-flurodeoxyglucose PET-CT scan and to compare it with standardized uptake value-based response evaluation on interim 18-flurodeoxyglucose PET-CT scan in patients of non-Hodgkin's lymphoma (diffuse large B-cell lymphoma).
    Gupta N; Singh N
    Nucl Med Commun; 2020 Apr; 41(4):395-404. PubMed ID: 32073552
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Functional Parameters of
    Yang J; Zhu S; Pang F; Xu M; Dong Y; Hao J; Ma X
    Contrast Media Mol Imaging; 2018; 2018():8659826. PubMed ID: 30363729
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of different segmentation algorithms on metabolic tumor volume measured on 18F-FDG PET/CT of cervical primary squamous cell carcinoma.
    Xu W; Yu S; Ma Y; Liu C; Xin J
    Nucl Med Commun; 2017 Mar; 38(3):259-265. PubMed ID: 28118260
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic superiority of the National Comprehensive Cancer Network International Prognostic Index over pretreatment whole-body volumetric-metabolic FDG-PET/CT metrics in diffuse large B-cell lymphoma.
    Adams HJ; de Klerk JM; Fijnheer R; Heggelman BG; Dubois SV; Nievelstein RA; Kwee TC
    Eur J Haematol; 2015 Jun; 94(6):532-9. PubMed ID: 25311082
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High total metabolic tumor volume in PET/CT predicts worse prognosis in diffuse large B cell lymphoma patients with bone marrow involvement in rituximab era.
    Song MK; Yang DH; Lee GW; Lim SN; Shin S; Pak KJ; Kwon SY; Shim HK; Choi BH; Kim IS; Shin DH; Kim SG; Oh SY
    Leuk Res; 2016 Mar; 42():1-6. PubMed ID: 26851438
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Defining the optimal method for measuring baseline metabolic tumour volume in diffuse large B cell lymphoma.
    Ilyas H; Mikhaeel NG; Dunn JT; Rahman F; Møller H; Smith D; Barrington SF
    Eur J Nucl Med Mol Imaging; 2018 Jul; 45(7):1142-1154. PubMed ID: 29460024
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk stratification in diffuse large B-cell lymphoma using lesion dissemination and metabolic tumor burden calculated from baseline PET/CT
    Cottereau AS; Meignan M; Nioche C; Capobianco N; Clerc J; Chartier L; Vercellino L; Casasnovas O; Thieblemont C; Buvat I
    Ann Oncol; 2021 Mar; 32(3):404-411. PubMed ID: 33278600
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Baseline
    Aide N; Fruchart C; Nganoa C; Gac AC; Lasnon C
    Eur Radiol; 2020 Aug; 30(8):4623-4632. PubMed ID: 32248365
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Methodological Aspects and the Prognostic Value of Metabolic Tumor Volume assessed with 18F-FDG PET/CT in Lymphomas.
    Tutino F; Giovannini E; Pastorino S; Ferrando O; Giovacchini G; Ciarmiello A
    Curr Radiopharm; 2022; 15(4):259-270. PubMed ID: 35352655
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinically feasible semi-automatic workflows for measuring metabolically active tumour volume in metastatic melanoma.
    van Sluis J; de Heer EC; Boellaard M; Jalving M; Brouwers AH; Boellaard R
    Eur J Nucl Med Mol Imaging; 2021 May; 48(5):1498-1510. PubMed ID: 33099667
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The prognostic significance of whole-body and spleen MTV (metabolic tumor volume) scanning for patients with diffuse large B cell lymphoma.
    Yamanaka S; Miyagawa M; Sugawara Y; Hasebe S; Fujii T; Takeuchi K; Tanaka K; Yakushijin Y
    Int J Clin Oncol; 2021 Jan; 26(1):225-232. PubMed ID: 33097970
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.